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Objective: to compare the general and specific health-related quality of life (HRQoL) between 
the Intervention (IG) and Control (CG) groups of coronary artery disease patients after the 
implementation of Action Planning and Coping Planning strategies for medication adherence 
and to verify the relationship between adherence and HRQoL. Method: this was a controlled and 
randomized study. Results: the sample (n=115) was randomized into two groups, IG (n=59) and 
CG (n=56). Measures of medication adherence and general and specific HRQoL were obtained 
in the baseline and after two months of monitoring. Conclusion: the findings showed that the 
combination of intervention strategies - Action Planning and Coping Planning for medication 
adherence did not affect the HRQoL of coronary artery disease patients in outpatient monitoring.
Descriptors: Nursing; Medication Adherence; Health Behavior; Planning Techniques; Coronary 
Disease.
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Introduction
Patient adherence to medication therapy is essential 
for the control of coronary artery disease (CAD) and 
prevention of its complications(1), constituting one of 
the biggest challenges for the nursing care to coronary 
disease patients, given the high percentage of non-
adherence to the therapeutic medication regimen(2). This 
construct refers to the extent to which patients follow 
the instructions of their physician or other healthcare 
professionals(3). It is a complex phenomenon influenced 
by a range of factors, including, individual beliefs, 
skills, financial resources and/or barriers, and social 
influences(3). Among the causes of non-adherence, the 
need for continued treatment can be highlighted, as 
well as the perceived lack of immediate benefits, the 
potential for adverse effects, and the costs associated 
with the treatment(3).
Medication adherence can have significant 
impact on the health-related quality of life (HRQoL) in 
patients with chronic clinical conditions(4-5), including 
CAD(6). Although they are different constructs, 
adherence and HRQoL are related to patients and 
should be considered when evaluating the impact of 
interventions that affect their health(7). Furthermore, 
these constructs are considered distinct outcomes 
in the care process - while adherence constitutes an 
intermediate result, HRQoL can be understood as a 
final outcome of the treatment(7). Thus, it is possible 
to assume that interventions outlined for optimizing 
adherence influence medication adherence a priori and 
subsequently the HRQoL.
Although targeted at different health conditions, 
some studies have investigated the relationship between 
HRQoL and adherence. Among these, cross-sectional 
studies with geriatric hypertensive patients(5), the use of 
medication for treatment of acquired immunodeficiency 
syndrome(8) and treatment with lipid-lowering drugs(9) 
can be highlighted. A recent literature review showed 
that few longitudinal studies have evaluated the impact 
of a theory-based intervention for the promotion or 
optimization of medication adherence on the general 
and specific HRQoL of patients with chronic(10) clinical 
conditions, especially among CAD patients.
Considering the importance of medication 
adherence and HRQoL in CAD secondary prevention 
programs, this study aimed to compare the general and 
specific HRQoL measures of coronary artery disease 
patients randomized into the intervention group (IG) and 
control group (CG) before and after the implementation 
of Action Planning and Coping Planning strategies for 
medication adherence, and to verify the relationship 
between medication adherence and general and specific 
HRQoL throughout the monitoring.
Methods
Subjects and Procedures
Data from this study are derived from a broader 
experimental study(11) that evaluated the effect of 
planning strategies on medication adherence and 
HRQoL of coronary artery disease patients. The sample 
consisted of CAD patients aged over 18, with prior 
clinical manifestation of angina or myocardial infarction 
(MI), with more than six months since the last ischemic 
event, and undergoing outpatient monitoring at one of 
the two hospitals in the state of São Paulo. Those who 
demonstrated an ability to communicate verbally and 
had been continuously using at least two oral drugs for 
CAD treatment (cardio protective and symptom relief 
medications) for at least a month were included. Those 
whose pharmacological treatment has been suspended 
or modified at the time of the initial approach (T0) were 
excluded. The participation of those patients who did 
not attend the scheduled follow-up appointments at 
one (T1) and two months (T2) after the baseline was 
discontinued, as well as those whose pharmacological 
therapy was suspended or modified during the 
monitoring period.
Sample
After the acceptance of the invitation to participate 
in the study and provision of the formal consent by 
signing the Terms of  Informed Consent, the subjects 
were randomized into control group (CG) or intervention 
group (IG). The aleatorization was based on a random 
sequence list generated by the SAS, version 9.1.3 
program (SAS Institute Inc., Cary NC, USA, 2002-2003). 
The patients of the IG were submitted to the planning 
strategies - Action Planning and Coping Planning, applied 
by the main researcher; while the patients in the CG 
received usual care.
Data Collection
Data were gathered from June 2010 to May 2011, 
using structured interviews and consultation of the 
hospital medical records at two different times:
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- T0 (baseline): interview and consent of the patient 
to participate in the study obtained by signing the 
term. Data related to sociodemographic and clinical 
characterization, medication adherence(12), factors 
related to non-adherence(13) and general and specific(15) 
HRQoL(14) were obtained;
- T2 (two months after T0): adherence and HRQoL 
measures were again obtained.
Intervention
The intervention was applied at T0 with only those 
patients in the IG and consisted of the formulation and 
implementation of plans, according to the theoretical 
assumptions of Implementation Intention(16-17), based 
on a previous Brazilian study(18). Patients were asked to 
design, in conjunction with the researcher, action and 
coping plans related to medication adherence. At T1 (one 
month after T0) presential reinforcement of the planning 
strategies was performed, by reading together the plans 
prepared at T0. The details of the intervention can be 
found in a previous study(11).
Control
The patients allocated to the CG received the 
routine care of the unit, which consisted of the usual 
clinical monitoring performed at the outpatient clinic. 
They were instructed to maintain their routine activities 
as well as their clinical follow-up appointments with the 
physician.
Instruments
- The Morisky Self-Reported Measure of Medication 
Adherence Scale(13): composed of four questions relating 
to non-adherence to pharmacological treatment, 
structured in Likert-type scales with four or five answer 
choices, the sum of which generates a score ranging 
from 4 up to 18; the lower the score the higher the 
favorability to adherence.
- Proportion of medication adherence (Proporção de 
adesão medicamentosa)(12): constructed to identify 
and quantify medications and their form of use. It 
includes the following variables: Name, strength and 
dosage of the prescribed medications; Description of 
the form of use of each medication, according to the 
strength and dosage, in the previous 24 hours; in the 
previous week, and in the month prior to the interview. 
Adherence was calculated based on self-reported 
missed doses, using the calculation: [(Prescribed 
doses - missed doses) x 100 / prescribed doses](19). 
Those who obtained a percentage of consumption of 
prescribed medications, equal to or greater than 80%(20) 
were considered “Adherent”. For those who used more 
than one medication, the proportion of adherence 
was calculated through the mean of the percentages 
of adherence to each medication(12). The proportion of 
adherence was analyzed as a continuous and binary 
variable - appropriate dose (dose used ≥80% of the 
prescribed dose) and inappropriate dose (dose <80% 
of the prescribed dose).
- Overall adherence assessment: the number and 
frequency of medications taken were evaluated, 
as well as their association with temporal markers: 
fasting, breakfast, lunch and dinner. This was 
evaluated based on the following classification: Group 
I (appropriate dosage and care for the prescription); 
Group II (appropriate dosage and inappropriate care), 
Group III (inappropriate dosage and appropriate 
care) and Group IV (inappropriate dosage and care). 
The patients classified in group I were considered 
“Adherent”, and those classified in groups II, III, and 
IV “Non-adherent” (12). 
- The MacNew Heart Disease Health-related Quality of 
Life Questionnaire (MacNew): consists of a modified 
version of the “Quality of Life after Myocardial 
Infarction” (QLMI) original(21) instrument and is 
composed of the domains: Physical Functioning (13 
items), Emotional Functioning (14 items) and Social 
Functioning (13 items). An item can be part of more 
than one domain. The maximum possible score in 
any domain is seven (indicating the best HRQoL) and 
the minimum is one (suggesting the worst HRQoL). 
Items not answered do not contribute to the score 
and item 27 (sexual relations) can be excluded 
without affecting the final score of the domain. 
Domain scores are calculated through the arithmetic 
mean of the responses of that domain. If more than 
50% of the items of a domain are not answered, the 
score for that domain is not calculated. The total 
score is calculated through the arithmetic mean of 
all the items answered, unless one of the domains 
is completely missing(22). The Brazilian version of 
MacNew(15) is considered reliable, valid and simple to 
apply(15,23). In the present study the reliability with 
respect to the internal consistency, assessed through 
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Cronbach’s alpha coefficient, ranged between 0.80 
and 0.90 throughout the monitoring.
- The 36-item Short Form Health Survey - SF-36: is a 
generic evaluation instrument of the perceived health 
status(24), which is easy to administer and comprehend. It 
consists of eight domains: Functional Capacity (ten items), 
Physical Aspects (four items), Pain (two items), General 
Health Status (five items), Vitality (four items), Social 
Aspects (two items), Emotional Aspects (three items), 
Mental Health (five items), and one question comparing the 
current health conditions with those of one year previous. 
The final score ranges from zero (worst health status) up 
to 100 (best health status)(24). The Brazilian version of the 
SF-36(14) was used and, in the present study, the internal 
consistency, assessed through Cronbach’s alpha coefficient, 
ranged between 0.80 and 0.90 throughout the monitoring.
Data Analysis
Descriptive analyzes were performed to characterize 
the sample according to sociodemographic, clinical, 
medication adherence, and HRQoL variables. Student’s 
t-test was used to check for differences between 
sociodemographic and clinical variables and the general 
and specific HRQoL between the IG and CG groups at 
T0. The paired Student’s t-test was used to check for 
differences in the HRQoL means between the pre- (T0) 
and post-intervention (T2) times. Simple linear regression 
analyzes were used to evaluate change in the HRQoL at 
T2. Pearson’s correlation coefficient was used to verify 
the relationship between medication adherence and 
HRQoL. Correlation coefficients < 0.30 were considered 
of weak magnitude, between 0.30 and 0.50 as moderate 
and > 0.50 of strong magnitude(25). The significance level 
adopted for the statistical tests was p ≤ 0.05.
Ethical Aspects
The study was approved by the Research Ethics 
Committee of a university in the state of São Paulo 
(Document No. 802/2009) and the Research Ethics 
Committee of a municipal hospital in the state of 
São Paulo (Document No. 001-11), as determined by 
Resolution No. 196/96 of the National Health Council/
Ministry of Health. Patients were invited to participate in 
the study through the explanation and careful reading 
of the consent form, being informed about the aims of 
the study and data collection procedure, as well as the 
voluntary nature of their participation, their guaranteed 
anonymity and freedom to withdraw at any time without 
any loss regarding healthcare. 
Results
Sociodemographic and clinical Characterization
At T0, 134 patients were considered eligible for the 
study. Of these, 8 were excluded due to the presence 
of at least one exclusion criterion. Thus, the sample 
consisted of 126 patients, of whom 62 were allocated 
to the CG and 64 to the IG. After the first approach, 5 
patients were excluded from the CG and 6 from the IG 
due to non-attendance of the scheduled appointments. 
Thus, 115 patients completed the study (CG= 56; IG= 
59). The comparative analysis between the groups at 
T0 showed that there were no differences between the 
groups regarding the sociodemographic and clinical 
variables, except for the number of previous myocardial 
infarctions, which was significantly higher in the IG 
(p=0.02).
The majority of the subjects consumed a mean 
of 6.4 (2.0) types of medication, with a mean of 3.6 
(0.6) cardioprotective medications, and 0.8 (0.7) 
symptom relief medications. When using the proportion 
of adherence and the Morisky adherence scale, it 
was observed that the group was characterized by 
non-adherence. When considering the proportion of 
adherence in association with appropriate care, the 
majority was classified as non-adherent. However, in 
the IG there was a significant percentage of individuals 
Table 1 - Sociodemographic and clinical characterization of the Total 115 patients with Coronary Artery Disease and of the 
patients in the Intervention Group (n=59) and Control Group (n=56) in the baseline (T0). Campinas, SP, Brazil, 2010-2011
Variables Total Group(n=115)
Intervention Group
(N=59)
Control Group
(N=56)
Sociodemographic
Age, Mean (SD*) 62.0 (9.0) 63.4 (8.9) 60.6 (9.0)
Gender, n (%)
Male 75 (65.2) 40 (67.8) 35 (62.5)
(continue...)
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that were adherent, when using the overall evaluation of 
adherence measure (p=0.023) (Table 1).
Analysis of Health Related Quality of Life (HRQoL) 
measures
Regarding the specific HRQoL (MacNew), significantly 
higher mean scores (p<0.05) for all domains of the 
MacNew were observed in the IG at T2, when compared 
to the baseline (T0). However, a significant increase in the 
scores of the majority of the MacNew domains was also 
observed in the CG, except in the emotional functioning 
domain, however, these differences were not statistically 
significant (Table 2). Regarding the generic HRQoL, 
significantly higher scores at T2 were observed in the 
IG in the Functional Capacity (p<0.001) and Emotional 
Variables Total Group(n=115)
Intervention Group
(N=59)
Control Group
(N=56)
Marital Arrangement, n (%)
With partner 83 (72.2) 44 (74.6) 39 (69.6)
Education (years), Mean (SD*) 5.8 (4.1) 5.5 (4.0) 6.2 (4.3)
Habits/Lifestyle, n (%)
Current smoker (yes) 13 (11.3) 3 (5.1) 10 (17.8)
Employment Situation, n (%)
Unemployed 71 (61.7) 44 (74.6) 33 (58.9)
Employed 31 (26.9) 9 (15.2) 22 (39.3)
Housewife/husband 10 (8.7) 5 (8.5) 5 (8.9)
Family income (MW†), Mean (SD*) 3.0 (3.6) 3.2 (3.6) 2.7 (3.5)
Clinical
Characterization of coronary disease, n (%)
Unstable Angina 24 (20.9) 15 (25.4) 9 (16.1)
Myocardial infarction 91 (79.1) 44 (74.5) 47 (83.9)
Number of previous infarctions, Mean (SD*) 0.7 (1.1) 1.0 (1.3)‡ 0.5 (0.9)‡
Symptoms (in the previous month)§, n (%)
Precordialgia 51 (44.3) 31 (52.5) 20 (35.7)
Dyspnoea 48 (41.7) 24 (40.7) 24 (42.8)
Lower limb edema 40 (34.8) 23 (39.0) 17 (30.3)
Palpitations 32 (27.8) 18 (30.5) 14 (25.0)
Lipothymy 27 (23.5) 16 (27.1) 11 (19.6)
Number of Associated Clinical Conditions, Mean (SD*) 5.0 (1.8) 5.1 (1.9) 4.8 (1.8)
Associated Clinical Conditions§, n (%)
Dyslipidemia 91 (79.1) 51 (86.4) 40 (71.4)
Arterial Hypertension 88 (76.5) 50 (84.7) 38 (67.8)
Diabetes mellitus 41 (35.6) 27 (45.8) 14 (25.0)
Treatment, n (%)
Clinical and Intervention (MR||/MRA¶/MR|| and MRA¶) 84 (73.0) 40 (67.4) 44 (78.6)
Clinical 31 (27.0) 19 (32.2) 12 (21.4)
Number of medications in use, Mean (SD*) 6.4 (2.0) 6.8 (2.0) 5.9 (1.9)
Number of Cardioprotective Medications, Mean (SD*) 3.6 (0.6) 3.5 (0.6) 3.7 (0.5)
Number of Symptom Relief Medications, Mean (SD*) 0.8 (0.7) 0.9 (0.7) 0.8(0.8)
Total Morisky score, Mean (SD*) 6.9 (2.8) 7.3 (3.1) 6.5 (2.3)
Proportion of Adherence, Mean (SD*) 92.9 (12.1) 92.1 (13.7) 93.7 (10.2)
Proportion of Adherence§, n (%)
Appropriate dose (≥80%) 53 (89.8) 52 (88.1) 50 (89.3)
Inappropriate dose (<80%) 6 (10.2) 7 (11.9) 6 (10.7)
Overall adherence assessment§, n (%)
Adherent 27 (23.5) 19 (32.2) 8 (14.3)
Non-Adherent 88 (76.5) 40 (67.8) 48 (85.7)
*Standard Deviation
†Minimum wage (R$ 545.00)
‡Student’s t test, p=0.02
§Percentage per line
||Surgical Myocardial Revascularization
¶ Myocardial Revascularization by Angioplasty
Table 1 - (continuation)
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Aspects (p<0.05) domains, when compared to the scores 
obtained at T0. In the CG no significant differences were 
observed between the scores obtained at T2 and T0.
While the intervention explained 5% of the 
variability of the proportion of adherence measure(11), the 
linear regression analysis showed that the Intervention 
was not able to explain the variability of the general and 
specific HRQoL measures.
Relationship between Adherence and Health Related 
Quality of Life 
Regarding the correlations between the Morisky 
scale scores and those of the specific HRQoL, the 
absence of correlations was found in the IG, at T0. 
However, at T2, low magnitude negative correlations 
were observed with the Physical Functioning (r=-0.29; 
p=0.04), Emotional Functioning (r=-0.27; p=0.04) 
and Total Score (r=-0.29; p=0.04) domains of the 
MacNew, indicating that the higher the specific HRQoL, 
the greater the medication adherence. In the CG, at T0, 
a significant moderate magnitude negative correlation 
was found between the Morisky adherence measure 
and Emotional Functioning domain of the MacNew 
(r=-0.31; p=0.02). At T2, no correlations were found 
between the Morisky adherence scale and the specific 
HRQoL measure.
In the IG, at T0, no correlations were found between 
the Morisky adherence scale and the generic HRQoL. 
At T2 a weak positive correlation was found between 
the total score of the Morisky scale and the Emotional 
Aspects domain (r=0.27; p=0.04) of the SF-36, contrary 
to the previously established hypotheses. In the CG, 
at T0, weak negative correlations were found between 
the Morisky scale and the Pain (r=-0.26; p=0.05) and 
Mental Health (r=-0.29; p=0.03) domains, indicating 
that the better generic HRQoL the higher the favorability 
for adherence. At T2 no significant correlations were 
found for this group.
In the IG at T0, no correlations were found between 
the proportion of adherence and the specific HRQoL. 
At T2, significant weak to moderate correlations were 
observed between the proportion of adherence and 
the Social Functioning domain (r=0.34; p=0.01) 
and Total Score (r=0.29; p=0.04) of the MacNew, 
indicating that the higher the specific HRQoL the better 
the adherence. However, in the CG at T0, a negative 
correlation was found between the proportion of 
adherence and the Social Aspect domain (r= -0.28; 
p=0.04) of the MacNew, contradicting the previously 
formulated hypotheses. No significant correlations 
were found at T2.
With regard to the relationship between the 
proportion of adherence and the general HRQoL 
Table 2 - Descriptive analysis of the scores of general (SF-36) and specific (MacNew) Health Related Quality of Life 
of coronary disease patients distributed into intervention group (n=59) and control group (n=62), at T0 and T2. 
Campinas, SP, Brazil, 2010-2011
Intervention Group (n=59) Control Group (n=56)
T0 T2 Mean 
differences 
(T2-T0)
T0 T2 Mean differences 
(T2-T0)Mean (SD*) Mean (SD*) Mean (SD*) Mean (SD*)
MacNew
Physical Functioning 4.8 (1.2) 5.2 (1.1) 0.4† 5.0 (1.3) 5.3 (1.1) 0.3‡
Emotional Functioning 4.9 (1.1) 5.2 (0.9) 0.3† 5.2 (1.3) 5.4 (1.1) 0.2
Social Functioning 4.7 (1.2) 5.1 (1.1) 0.4† 5.0 (1.2) 5.3 (1.1) 0.3†
Total 4.8 (1.0) 5.1 (0.9) 0.3† 5.0 (1.1) 5.3 (1.0) 0.3†
SF-36
Functional Capacity 49.1 (22.3) 54.4 (28.7) 5.3† 55.4 (28.4) 58.4 (27.8) 3.0
Physical Aspects 39.0 (29.1) 36.9 (38.1) -2.1 43.7 (40.5) 44.2 (39.3) 0.5
Pain 55.8 (24.3) 61.2 (25.7) 5.4 56.5 (28.0) 58.5 (27.2) 2.0
General Health Status 59.0 (20.6) 61.1 (17.4) 2.1 60.2 (21.6) 57.4 (18.7) -2.8
Vitality 56.2 (23.2) 56.3 (21.1) 0.1 56.4 (22.9) 54.3 (21.9) -2.1
Social Aspects 60.4 (28.0) 70.8 (25.9) 10.4† 64.3 (29.6) 69.4 (26.6) 5.1
Emotional Aspects 42.4 (39.1) 51.4 (41.2) 9.0 49.4 (41.2) 55.9 (38.2) 6.5
Mental Health 61.4 (22.3) 62.4 (19.6) 1.0 63.1 (22.2) 62.6 (21.0) -0.5
*Standard Deviation
†p<0.05
‡p<0.001 - paired t-test
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measure, in the IG at T0, a weak correlation was found 
with the General Health Status domain (r=0.26; 
p=0.05) of the SF-36. At T2 a moderate positive 
correlation was observed between the Emotional Aspects 
domain (r=0.30; p=0.02) of the SF-36, confirming the 
previously established hypotheses. However, in the CG 
at T0, significant low to moderate negative correlations 
were found between the proportion of adherence and 
the General Health Status (r= -0.42; p=0.00) and Social 
Functioning (r=- 0.28; p=0.04) domains of the SF-36, 
contrary to the previously established hypotheses. At 
T2 a significant moderate negative correlation was also 
found between the proportion of adherence and the 
General Health Status domain of the SF-36 (r=-0.28; 
p=0.03).
Discussion
This study aimed to compare the general and specific 
HRQoL of coronary artery disease patients allocated in 
IG and CG after implementing an intervention based 
on Action Planning and Coping Planning strategies for 
medication adherence, as well as to verify the existence 
of a relationship between adherence and HRQoL over 
two months of monitoring.
The findings indicate that at T2, the IG patients 
presented a significant increase in mean scores in all the 
MacNew domains as well as the Functional Capacity and 
Emotional Aspects domains of the SF-36 when compared 
to the scores obtained at the start of the study (T0). 
Weak to moderate associations were found between 
adherence and the specific measure of HRQoL. However, 
the findings were not consistent over the subsequent 
two months.
The relationship between adherence and specific 
HRQoL (MacNew) were found especially in the IG at the 
end of the two month monitoring (T2), for both measures 
employed - proportion of adherence and the Morisky 
scale. Significant low magnitude negative correlations 
were found between the Morisky scale and the Physical 
Functioning, Emotional Functioning domains and the 
Total Score of the MacNew and weak to moderate 
correlations between the proportion of adherence and 
the Social Functioning domain and Total Score of the 
MacNew. However, an unexpected correlation in the CG 
at T0 was observed between the proportion of adherence 
and the Social Functioning domain of the MacNew. In 
summary, the greater the favorability of adherence, the 
better the HRQoL in all domains and the Total Score of 
the MacNew.
In the analysis of the relationship between 
adherence and general HRQoL (SF-36) the correlations 
occurred at both times (T0 and T2) and in both groups 
(IG and CG). In the IG the relationship was highlighted 
between the proportion of adherence and the General 
Health Status (at T0) and Emotional Aspects (at T2) 
domains. In the IG, the Morisky measure of adherence 
did not correlate with the general HRQoL, except for 
an unexpected positive correlation with the Emotional 
Aspect domain. In the CG negative correlations were 
found between the Morisky adherence scale and the 
Pain and Mental Health domains, while the proportion 
of adherence correlated negatively and unexpectedly 
with the General Health Status (at T0 and T2) and Social 
Aspects (at T0) domains. These findings suggest that the 
relationship between adherence and general HRQoL is 
less consistent compared to the results of the specific 
measure.
In the present study, although the IG presented 
better HRQoL in all domains of the MacNew and in the 
Functional Capacity and Emotional State domains of 
the SF-36, the intervention was not able to explain the 
variability in HRQoL after two months of monitoring. 
One explanation for this finding is the limitation of 
self-reported measures in the accurate measurement 
of adherence, as well as the limited time period for 
applying the intervention to change behavior as complex 
as adherence.
The weak to moderate magnitude correlations 
between adherence and HRQoL reported in the literature 
and demonstrated in the present study are consistent 
with the current recognition that other factors, in 
addition to the physical and emotional, affect the HRQoL. 
The exact mechanism by which medication adherence is 
associated with HRQoL is still unknown, with suggestions 
that HRQoL is part of a complex network of psychosocial 
characteristics that influence the patient’s ability to cope 
with the chronicity of the disease(5) .
Previous findings(4) involving type 2 diabetic patients 
showed that medication adherence was not associated 
with the HRQoL domains. However, an association was 
observed with the combination of knowledge about the 
medical prescription and the attitude toward medication 
adherence, indicating the need for research into the 
determinant psychosocial variables for adherence 
behavior.
The absence or weak relationship between 
adherence and HRQoL were observed in other studies 
using self-reported measures(6) as well as those using 
electronic records of prescriptions(4,8). Thus, our results 
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may reflect the limitations of different methods used for 
measuring medication adherence. Another limitation is 
the fact that, in the sample studied, the determinant 
psychosocial variables for medication adherence that 
could lead to the better design of the intervention were 
unknown - whether motivational and/or motivational and 
volitional. Further studies are recommended in order to 
deepen the knowledge about the longitudinal relationship 
between adherence to cardioprotective and symptom 
relief medications and HRQoL. Further investigation 
into the possible mediating effect of motivational and 
volitional determinants in medication adherence is 
suggested. The elucidation of these relationships will 
contribute to the design of theory-based interventions 
that are most effective in promoting adherence and, 
consequently, in improving HRQoL among CAD patients.
Conclusion
The findings indicate that the intervention based 
on Action Planning and Coping Planning strategies 
for medication adherence did not affect the generic 
and specific measures of HRQoL in coronary disease 
outpatients. Regarding the relationship between 
adherence and HRQoL, significant, although weak 
to moderate, correlations were found between the 
medication adherence measures used in this study and 
the HRQoL measures, especially between medication 
adherence and the specific measure of HRQoL. Future 
studies are recommended in order to elucidate the 
psychosocial mediatory factors of the relationship 
between medication adherence and HRQoL, with a view 
to outlining nursing interventions effective in promoting 
medication adherence and improved HRQoL in patients 
suffering from coronary artery disease.
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